Recurrent TERT promoter mutations in non-small cell lung cancers

Lung Cancer

Volumn 86, Issue 3, 2014, Pages 369-373

  Ma, Xiao ^a,b   Gong, Ranxia ^a,b   Wang, Rui ^a,b   Pan, Yunjian ^a,b   Cai, Deng ^a,b   Pan, Bin ^a,b   Li, Yuan ^a,b   Xiang, Jiaqing ^a,b   Li, Hecheng ^a,b   Zhang, Jie ^a,b   Sun, Yihua ^a,b   Chen, Haiquan ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Clinicopathologic; Clinicopathological characteristics; Lung cancer; Recurrent; Target; TERT mutation

Indexed keywords

TELOMERASE REVERSE TRANSCRIPTASE; TELOMERASE; TERT PROTEIN, HUMAN;

ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ARTICLE; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; SARCOMATOID CARCINOMA; SMOKING; SOMATIC MUTATION; SQUAMOUS CELL CARCINOMA; VERY ELDERLY; ASIAN CONTINENTAL ANCESTRY GROUP; BIOSYNTHESIS; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; GENETICS; MUTATION; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROMOTER REGIONS, GENETIC; SMOKING; TELOMERASE;

EID: 84926175455     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.10.009     Document Type: Article

References (19)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Sant M., Aareleid T., Berrino F., Bielska M.L., Carli P.M., Faivre J., et al. EUROCARE-3: survival of cancer patients diagnosed 1990-94 - results and commentary. Ann Oncol 2003, 14(Suppl. 5):v61-v118.
3. Griewank K.G., Murali R., Schilling B., Schimming T., Moller I., Moll I., et al. TERT promoter mutations are frequent in cutaneous basal cell carcinoma and squamous cell carcinoma. PLOS ONE 2013, 8:e80354.
4. Huang F.W., Hodis E., Xu M.J., Kryukov G.V., Chin L., Garraway L.A. Highly recurrent TERT promoter mutations in human melanoma. Science 2013, 339:957-959.
5. Horn S., Figl A., Rachakonda P.S., Fischer C., Sucker A., Gast A., et al. TERT promoter mutations in familial and sporadic melanoma. Science 2013, 339:959-961.
6. Liu X., Bishop J., Shan Y., Pai S., Liu D., Murugan A.K., et al. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer 2013, 20:603-610.
7. Killela P.J., Reitman Z.J., Jiao Y., Betteqowda C., Aqrawal N., Diaz L.J., et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A 2013, 110:6021-6026.
8. Vinagre J., Almeida A., Pópulo H., Batista R., Lyra J., Pinto V., et al. Frequency of TERT promoter mutations in human cancers. Nat Commun 2013, 4:2185.
9. Heidenreich B., Nagore E., Rachakonda P.S., Garcia-Casado Z., Requena C., Traves V., et al. Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma. Nat Commun 2014, 26:3401.
10. Kinde I., Munari E., Faraj S.F., Hruban R.H., Schoenberg M., Bivalacqua T., et al. TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine. Cancer Res 2013, 73:7162-7167.
11. Nault J.C., Calderaro J., Tommaso L.D., Balabaud C., Zafrani E.S., Bioulac-Saqe P., et al. TERT promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. Hepatology 2014, 10.1002/hep.27372.
12. Gao B., Sun Y., Zhang J., Ren Y., Fang R., Han X., et al. Spectrum of LKB1, EGFR, and KRAS mutations in Chinese lung adenocarcinomas. J Thorac Oncol 2010, 5:1130-1135.
13. Detre S., Saclani Jotti G., Dowsett M. A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol 1995, 48:876-878.
14. Detterbeck F.C., Boffa D.J., Tanoue L.T. The new lung cancer staging system. Chest 2009, 136:260-271.
15. Low K.C., Tergaonkar V. Telomerase: central regulator of all of the hallmarks of cancer. Trends Biochem Sci 2013, 38:426-434.
16. Shay J.W., Zou Y., Hiyama E., Wright W.E. Telomerase and cancer. Hum Mol Genet 2001, 10:677-685.
17. Shay J.W., Wright W.E. Telomerase: a target for cancer therapeutics. Cancer Cell 2002, 2:257-265.
18. Marian C.O., Cho S.K., McEllin B.M., Maher K.J., Hatanpaa E.A., Madden C.J., et al. The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth. Clin Cancer Res 2010, 16:154-163.
19. Hu J., Hwang S.S., Liesa M., Gan B., Sahin E., Jaskelioff M., et al. Antitelomerase therapy provokes ALT and mitochondrial adaptive mechanisms in cancer. Cell 2012, 148:651-663.